Journal Information
Vol. 89. Issue 1.
Pages 40-47 (January - February 2013)
Share
Share
Download PDF
More article options
Vol. 89. Issue 1.
Pages 40-47 (January - February 2013)
Original article
Open Access
The Impact of Cystic Fibrosis on the Immunologic Profile of Pediatric Patients
Visits
4411
Daniela M. Bernardia,
Corresponding author
dani_miotto@yahoo.com.br

Corresponding author.
, Antonio F. Ribeirob, Tais N. Mazzolac, Maria M.S. Vilelad, Valdemiro C. Sgarbierie
a MSc in Food and Nutrition. Department of Food and Nutrition, School of Food Engineering, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil
b PhD in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
c MSc in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
d PhD in Biology (Immunology). Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
e PhD in Nutrition. Department of Food and Nutrition, School of Food Engineering, UNICAMP, Campinas, São Paulo, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Objective

To compare the immunologic state of 44 pediatric patients with cystic fibrosis (CF) with a control group consisting of 16 healthy individuals.

Methods

CF patients aged 3 to 12 years with moderate to good clinical score were selected for the study. Erythrocytic glutathione, production of reactive oxygen species, cytokines (TNF-a, IFN-g, IL-8, IL-6, IL-10) in peripheral blood mononuclear cells cultures under spontaneous and BCG- or PHA-stimulated conditions, serum concentrations of TGF-b2, IgA, IgG, IgM, IgE, and salivary IgA were evaluated.

Results

The spontaneous production of TNF-a, IL-6, and IL-10, the PHA-stimulated production of IL-6, and the serum TGF-b2, IgA, and IgG were increased in samples from CF patients. Healthy subjects had a higher production of TNF-a in response to BCG.

Conclusion

Although CF patients appeared clinically stable, the results of their peripheral blood examinations demonstrated an impact on the immune system.

Keywords:
Cystic fibrosis
Reactive oxygen species
Glutathione
Cytokines
Immunoglobulins
Resumo
Objetivo

Comparar o estado imunológico de 44 pacientes pediátricos com fibrose cística (FC) a um grupo-controle formado por 16 indivíduos saudáveis.

Métodos

Foram selecionados para o estudo pacientes com FC com idade entre 3 e 12 anos, apresentando um escore clínico moderado e bom. Foram avaliados a glutationa eritrocitária, a produção de espécies reativas de oxigênio, citocinas (TNF-a, IFN-g, IL-8, IL-6, IL-10) em culturas de células mononucleares do sangue periférico em condições espontâneas e estimuladas por BCG ou PHA, a concentração sérica de TGF-b2, IgA, IgG, IgM, IgE e IgA salivar.

Resultados

A produção espontânea de TNF-a, IL-6 e IL-10, a produção de IL-6 estimula- da por PHA e TGF-b2, IgA e IgG séricas aumentaram em amostras de pacientes com FC. Indivíduos saudáveis tiveram uma produção mais elevada de TNF-a em resposta a BCG.

Conclusão

Apesar de os pacientes com FC parecerem clinicamente estáveis, os resul- tados de seus exames de sangue periférico mostraram que houve um impacto sobre o sistema imunológico.

Palavras-chave:
Fibrose cística
Espécies reativas de oxigênio
Glutationa
Citocinas
Imunoglobulinas
Full text is only aviable in PDF
References
[1]
B.P. O'Sullivan, S.D. Freedman.
Cystic fibrosis.
Lancet., 373 (2009), pp. 1891-1904
[2]
J.C. Cheung, P. Kim Chiaw, S. Pasyk, C.E. Bear.
Molecular basis for the ATPase activity of CFTR.
Arch Biochem Biophys., 476 (2008), pp. 95-100
[3]
M. Rottner, J.M. Freyssinet, M.C. Martínez.
Mechanisms of the noxious inflammatory cycle in cystic fibrosis.
Respir Res., 10 (2009), pp. 23
[4]
T.S. Cohen, A. Prince.
Cystic fibrosis: a mucosal immunodeficiency syndrome.
Nat Med., 18 (2012), pp. 509-519
[5]
E. Beutler.
Red Cell Metabolism.
Churchill Livingstone, (1986),
[6]
A. Emmendörffer, M. Hecht, M.L. Lohmann-Matthes, J. Roesler.
A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123.
J Immunol Methods., 131 (1990), pp. 269-275
[7]
M.P. Richardson, M.J. Ayliffe, M. Helbert, E.G. Davies.
A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test.
J Immunol Methods., 219 (1998), pp. 187-193
[8]
H. Gaines, L. Andersson, G. Biberfeld.
A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry.
J Immunol Methods., 195 (1996), pp. 63-72
[9]
E. Boncoeur, V.S. Criq, E. Bonvin, T. Roque, A. Henrion-Caude, D.C. Gruenert, et al.
Oxidative stress induces extracellular signal- regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression.
Int J Biochem Cell Biol., 40 (2008), pp. 432-446
[10]
S. Mangione, D.D. Patel, B.R. Levin, S.B. Fiel.
Erythrocytic glutathione in cystic fibrosis. A possible marker of pulmonary dysfunction.
Chest., 105 (1994), pp. 1470-1473
[11]
L.C. Lands, V. Grey, A.A. Smountas, V.G. Kramer, D. McKenna.
Lymphocyte glutathione levels in children with cystic fibrosis.
Chest., 116 (1999), pp. 201-205
[12]
L. Gao, K.J. Kim, J.R. Yankaskas, H.J. Forman.
Abnormal glutathione transport in cystic fibrosis airway epithelia.
Am J Physiol., 277 (1999), pp. L113-L118
[13]
D. Norman, J.S. Elborn, S.M. Cordon, R.J. Rayner, M.S. Wiseman, E.J. Hiller, et al.
Plasma tumour necrosis factor alpha in cystic fibrosis.
Thorax., 46 (1991), pp. 91-95
[14]
K. Balough, M. McCubbin, M. Weinberger, W. Smits, R. Ahrens, R. Fick.
The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.
Pediatr Pulmonol., 20 (1995), pp. 63-70
[15]
T.L. Bonfield, J.R. Panuska, M.W. Konstan, K.A. Hilliard, J.B. Hilliard, H. Ghnaim, et al.
Inflammatory cytokines in cystic fibrosis lungs.
Am J Respir Crit Care Med., 152 (1995), pp. 2111-2118
[16]
E. Osika, J.M. Cavaillon, K. Chadelat, M. Boule, C. Fitting, G. Tournier, et al.
Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease.
Eur Respir J., 14 (1999), pp. 339-346
[17]
F. Karpati, F.L. Hjelte, B. Wretlind.
TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment.
Scand J Infect Dis., 32 (2000), pp. 75-79
[18]
A.L. Pukhalsky, N.I. Kapranov, E.A. Kalashnikova, G.V. Shmarina, L.A. Shabalova, S.N. Kokarovtseva, et al.
Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection.
Mediators Inflamm., 8 (1999), pp. 159-167
[19]
C. Moser, S. Kjaergaard, T. Pressler, A. Kharazmi, C. Koch, N. Høiby.
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.
APMIS., 108 (2000), pp. 329-335
[20]
C. Wojnarowski, T. Frischer, E. Hofbauer, C. Grabner, W. Mosgoeller, I. Eichler, et al.
Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation.
Eur Respir J., 14 (1999), pp. 1136-1144
[21]
T.L. Noah, H.R. Black, P.W. Cheng, R.E. Wood, M.W. Leigh.
Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.
J Infect Dis., 175 (1997), pp. 638-647
[22]
L.S. Nixon, B. Yung, S.C. Bell, J.S. Elborn, D.J. Shale.
Circulating immunoreactive interleukin-6 in cystic fibrosis.
Am J Respir Crit Care Med., 157 (1998), pp. 1764-1769
[23]
D. Nichols, J. Chmiel, M. Berger.
Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.
Clin Rev Allergy Immunol., 34 (2008), pp. 146-162
[24]
R.B. Moss, R.C. Bocian, Y.P. Hsu, Y.J. Dong, M. Kemna, T. Wei, et al.
Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR).
Clin Exp Immunol., 106 (1996), pp. 374-388
[25]
J.N. Rosensweig, M. Omori, K. Page, C.J. Potter, E.J. Perlman, S.S. Thorgeirsson, et al.
Transforming growth factor-beta1 in plasma and liver of children with liver disease.
Pediatr Res., 44 (1998), pp. 402-409
[26]
M.A. South, W.J. Warwick, F.A. Wolheim, R.A. Good.
The IgA system. 3. IgA levels in the serum and saliva of pediatric patients-evidence for a local immunological system.
J Pediatr., 71 (1967), pp. 645-653
[27]
E. Gugler, J.C. Pallavicini, H. Swedlow, I. Zipkin, P.A. Agnese.
Immunological studies of submaxillary saliva from patients with cystic fibrosis and from normal children.
J Pediatr., 73 (1968), pp. 548-559
[28]
M.E. Hodson, L. Morris, J.C. Batten.
Serum immunoglobulins and immunoglobulin G subclasses in cystic fibrosis related to the clinical state of the patient.
Eur Respir J., 1 (1988), pp. 701-705
[29]
W.J. Matthews Jr., M. Williams, B. Oliphint, R. Geha, H.R. Colten.
Hypogammaglobulinemia in patients with cystic fibrosis.
N Engl J Med., 302 (1980), pp. 245-249
[30]
W.B. Wheeler, M. Williams, W.J. Matthews Jr., H.R. Colten.
Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study.
J Pediatr., 104 (1984), pp. 695-699
[31]
F. Harrison.
Microbial ecology of the cystic fibrosis lung.
Microbiology., 153 (2007), pp. 917-923
[32]
D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
Am J Respir Crit Care Med., 175 (2007), pp. 367-416
[33]
T.M. Kremer, R.G. Zwerdling, P.H. Michelson, P. O'Sullivan.
Intensive care management of the patient with cystic fibrosis.
J Intensive Care Med., 23 (2008), pp. 159-177
[34]
J.W. Costerton, P.S. Stewart, E.P. Greenberg.
Bacterial biofilms: a common cause of persistent infections.
Science., 284 (1999), pp. 1318-1322
[35]
T.H. Ottenhoff.
New pathways of protective and pathological host defense to mycobacteria.
Trends Microbiol., 20 (2012), pp. 419-428
[36]
G.B. Pier.
The challenges and promises of new therapies for cystic fibrosis.
J Exp Med., 209 (2012), pp. 1235-1239

Please, cite this article as: Bernardi DM, Ribeiro AF, Mazzola TN, Vilela MM, Sgarbieri VC. The impact of cystic fibrosis on the immunologic profile of pediatric patients. J Pediatr (Rio J). 2013;89:40-47.

Copyright © 2013. Sociedade Brasileira de Pediatria
Download PDF
Idiomas
Jornal de Pediatria (English Edition)
Article options
Tools
en pt
Taxa de publicaçao Publication fee
Os artigos submetidos a partir de 1º de setembro de 2018, que forem aceitos para publicação no Jornal de Pediatria, estarão sujeitos a uma taxa para que tenham sua publicação garantida. O artigo aceito somente será publicado após a comprovação do pagamento da taxa de publicação. Ao submeterem o manuscrito a este jornal, os autores concordam com esses termos. A submissão dos manuscritos continua gratuita. Para mais informações, contate assessoria@jped.com.br. Articles submitted as of September 1, 2018, which are accepted for publication in the Jornal de Pediatria, will be subject to a fee to have their publication guaranteed. The accepted article will only be published after proof of the publication fee payment. By submitting the manuscript to this journal, the authors agree to these terms. Manuscript submission remains free of charge. For more information, contact assessoria@jped.com.br.
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.